Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > 30 million for breast cancer trial

<< Previous

Bullboard Posts

Next >>

Comment by inthnoon Sep 20, 2024 8:41am

64 Views

Post# 36232690

RE:RE:RE:RE:RE:RE:RE:30 million for breast cancer trial

At 3:35 of the presentation Kirk also states at 3-5 we will be well on our way into enrolling patients into both studies. Keep listening as Kirk then states that in 5 years if the data proves out that they will be submitting for approval in either 1 or both of the indications.

Noteable, did you even listen to the presentation as it clearly stated the timelines that they are hoping for and this is if the data proves out. The only thing that can help earlier is that IF the data proves out that they will be seeking AA but there is no guarantee.

<< Previous

Bullboard Posts

Next >>

The long-term forecast for lithium stocks in 2024